On September 17, GENSCRIPT BIO rose 5.96% in regular trading, trading at HK$34.22/share, with turnover of HK$106 million. The rally was driven by a combination of JPMorgan's significant stake increase and robust first-half financial results.
JPMorgan acquired approximately 16.72 million shares on September 11 at an average price of HK$32.02 per share via an off-market transaction, totaling approximately HK$535 million. Following the purchase, JPMorgan's long position rose from 6.72% to 7.48%, with total holdings reaching approximately 165 million shares. The bank reiterated its Overweight rating and HK$41 target price, citing sustained AIDD order momentum and stable capacity utilization.
Meanwhile, the company reported H1 revenue of US$404 million, up 27.3% year-over-year, with adjusted net profit surging 203.3% to US$62.52 million. Gross profit rose 48.0% to US$207 million. The life sciences segment contributed US$319 million in revenue, up 28.8%, primarily driven by AI-driven drug discovery and rising antibody drug demand. The company also recently completed a placement of 77.13 million new shares at HK$30.50 each, raising net proceeds of approximately HK$2.33 billion, with around 70% earmarked for expanding AIDD platform capacity.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments